

## Sterne Kessler Goldstein Fox

ATTORNEYS AT LAW



Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Edward W. Yee Grant E. Reed Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenberg Iracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Imothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou W. Blake Coblentz James J. Pohl John T. Haran

Mark W. Rygiel Michael R. Malek\* Carla Ji-Eun Kim Doyle A. Siever\* Ulrike Winkler Jenks Paul A. Cahvo Robert A. Schwartzman C. Matthew Rozier\* Shameek Ghose Randall K. Baldwin Daniel J. Nevrhy

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist

\*Admitted only in Maryland \*Admitted only in Virginia \*Practice Limited to Federal Agencies

November 16, 2007

WRITER'S DIRECT NUMBER: (202) 772-8684 INTERNET ADDRESS: DLETTING@SKGF.COM

Art Unit 1646

Attn: Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/535,458; Filed: November 20, 2003

For: Novel Gene Targets and Ligands That Bind Thereto for Treatment

and Diagnosis of Colon Carcinomas

Inventors: MCLACHLAN et al.

Our Ref: 2159.0640005/EKS/PAC/DLL

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. SKGF Cover Letter;
- 2. Information Disclosure Statement;
- 5 sheets of IDS Forms (PTO/SB/08A/B) listing the cited documents (FP1 and NPL1-NPL31);
- 4. Copies of the cited documents (FP1 and NPL1-NPL31); and
- 5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLL.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents November 16, 2007 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Danielle L. Letting Agent for Applicants

Registration No. 56,971

PAC/DLL/bls Enclosures

729144\_1.DOC

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f202.371.2540: www.skgf.com

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MCLACHLAN et al.

Appl. No.: 10/535,458

(U.S. Nat'l Phase of Int'l Appl.

No. PCT/US03/37206)

Int'l Filing date: November 20, 2003

For: Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon

Carcinomas

Confirmation No.: 1633

Art Unit: 1646

Examiner: To Be Assigned

Atty. Docket: 2159.0640005/EKS/PAC/DLL

## Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents, FP1 and NPL1 to NPL31, are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of U.S. patent, citied on the attached Form PTO/SB/08A as document US1, is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Danielle L. Letting
Agent for Applicants

Registration No. 56,971

Date: 11.16.2007

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

625803v1